Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMyriad Genetics Inc

Myriad Genetics Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
5.92 USD -0.37 ( 5.88%)
Last update at 2026-11-06T21:08:00Z
VOLUME
2561435
Market Cap
371.12M

Momentum Score

…

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.89
Low
6.36
High
52 Week Price Range
2.74
Low
8.59
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
6.29
Dividend Yield
-
Revenue TTM
557.00M
Revenue Per Share
7.45
Gross Profit TTM
379.10M
Debt / Equity
0.57
ROE
-23.51%
Net Debt
60.20M
ROCE
-67.14%
Diluted EPS TTM
-1.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Income before tax -395.10M -123.50M -262.20M -140.60M -140.60M
Minority interest - - - 0.00M 0.00M
Net income -365.90M -127.30M -263.30M -112.00M -112.00M
Selling general administrative 256.80M 275.90M 283.70M 514.70M 247.90M
Selling and marketing expenses 280.80M 284.10M 289.20M - 266.80M
Gross profit 576.60M 585.40M 517.00M 476.40M 476.40M
Reconciled depreciation 53.70M 61.20M 61.90M 52.70M 52.70M
Ebit -384.60M -120.70M -259.30M -123.70M -137.40M
Ebitda -330.90M -59.50M -197.40M -67.80M -84.70M
Depreciation and amortization 53.70M 61.20M 61.90M 55.90M 52.70M
Operating income -67.80M -88.00M -144.60M -123.70M -123.70M
Other operating expenses 892.30M 925.60M 897.80M 802.10M 802.10M
Interest expense 10.50M 2.80M 2.90M 3.20M 3.20M
Tax provision -29.20M 3.80M 1.10M -28.60M -28.60M
Interest income 1.80M 1.70M 2.50M 2.60M 2.60M
Net interest income -8.70M -1.10M -0.40M -0.60M -0.60M
Income tax expense -29.20M 3.80M 1.10M -28.60M -28.60M
Total revenue 824.50M 837.60M 753.20M 678.40M 678.40M
Total operating expenses 644.40M 673.40M 661.60M 600.10M 600.10M
Cost of revenue 247.90M 252.20M 236.20M 202.00M 202.00M
Total other income expense net -327.30M -35.50M -117.60M -16.90M -16.90M
Net income from continuing ops -365.90M -127.30M -263.30M -112.00M -112.00M
Net income applicable to common shares - - - -112.00M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Total assets 706.60M 1027.60M 1146.50M 1198.70M 1198.70M
Intangible assets 153.40M 262.40M 349.50M 379.70M 379.70M
Other current assets 37.10M 46.90M 36.40M 20.40M 38.00M
Total liab 338.60M 326.50M 363.30M 312.90M 312.90M
Total stockholder equity 368.00M 701.10M 783.20M 885.80M 885.80M
Other current liab 96.90M 113.90M 109.30M 93.70M 88.90M
Common stock 0.90M 0.90M 0.90M 0.80M 0.80M
Capital stock 0.90M 0.90M 0.90M 0.80M 0.80M
Retained earnings -1122.70M -756.80M -629.50M -366.20M -366.20M
Other liab - - - 44.80M -
Good will 51.60M 286.30M 287.40M 286.80M 286.80M
Other assets - - - 8.40M -
Cash 149.60M 102.40M 132.10M 56.90M 56.90M
Total current liabilities 133.80M 164.10M 155.90M 137.20M 137.20M
Current deferred revenue - - - 0.60M 0.60M
Net debt 60.20M 37.90M 20.00M 88.10M 88.10M
Short term debt 6.90M 12.80M 16.20M 14.10M 14.10M
Short long term debt total 209.80M 140.30M 152.10M 145.00M 145.00M
Other stockholder equity 1489.00M 1457.80M 1415.50M 1260.10M 1260.10M
Property plant equipment - - - 187.30M -
Total current assets 332.60M 298.00M 313.60M 274.60M 274.60M
Long term investments - - 0.00M 54.80M 54.80M
Net tangible assets - - - 212.20M -
Short term investments - 0.00M 8.80M 58.00M 58.00M
Net receivables 115.30M 121.20M 114.30M 101.60M 101.60M
Long term debt 119.90M 39.60M 38.50M - -
Inventory 30.60M 27.50M 22.00M 20.10M 20.10M
Accounts payable 30.00M 32.30M 25.80M 28.80M 28.80M
Accumulated other comprehensive income 0.80M -0.80M -3.70M -8.90M -8.90M
Non currrent assets other 5.60M 8.50M 15.40M 15.50M 15.50M
Non current assets total 374.00M 729.60M 832.90M 924.10M 924.10M
Capital lease obligations 89.90M 100.70M 113.60M 145.00M 145.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Investments 0.00M -11.90M 31.90M -77.50M -77.50M
Change to liabilities - - - -8.50M -
Total cashflows from investing activities -27.40M -11.90M 31.90M -77.50M -77.50M
Net borrowings 84.30M 0.10M 39.80M - 0.00M
Total cash from financing activities 64.20M -7.40M 152.90M -8.00M -8.00M
Change to operating activities - - - -80.50M -
Net income -365.90M -127.30M -263.30M -112.00M -112.00M
Change in cash 39.40M -29.00M 74.50M -192.40M -192.40M
Begin period cash flow 111.90M 140.90M 66.40M 258.80M 258.80M
End period cash flow 151.30M 111.90M 140.90M 66.40M 66.40M
Total cash from operating activities 1.80M -8.70M -110.90M -106.30M -106.30M
Issuance of capital stock 0.00M 0.00M 117.60M - 0.00M
Depreciation 53.70M 61.20M 61.90M 52.70M 52.70M
Other cashflows from investing activities -27.40M - - - -
Change to inventory -3.20M -6.20M -1.80M -2.90M -2.90M
Change to account receivables 6.20M -8.70M 3.80M -10.30M 7.70M
Other cashflows from financing activities -23.40M -7.50M -4.50M -14.30M -14.30M
Change to netincome - - - 54.50M -
Capital expenditures 27.40M 29.70M 73.30M 45.30M 45.30M
Change in working capital -19.30M -54.40M 27.00M -101.50M -83.50M
Stock based compensation 35.20M 49.80M 40.70M 38.10M 38.10M
Other non cash items 330.50M 62.30M 23.40M 48.30M 30.30M
Free cash flow -25.60M -38.40M -184.20M -151.60M -151.60M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MYGN
Myriad Genetics Inc		 -0.37
5.88%		 5.92 - 54.05 0.67 1.19 0.57 -23.47
TMO
Thermo Fisher Scientific Inc		 17.82
2.63%		 694.76 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.91
1.73%		 230.25 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.45 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.31
1.23%		 24.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Myriad Genetics Inc

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

322 North 2200 West, Salt Lake City, UT, United States, 84116

801 584 3600

https://www.myriad.com

2700

Name Title Year Born
Mr. Paul J. Diaz CEO, Pres & Director 1962
Mr. R. Bryan Riggsbee Exec. VP, CFO & Treasurer 1971
Ms. Nicole Lambert Chief Operating Officer 1974
Mr. Mark S. Verratti Chief Commercial Officer 1968
Ms. Natalie Munk Principal Accounting Officer 1981
Dr. Kevin Richard Haas Chief Technology Officer 1986
Dr. Dale Muzzey Ph.D. Chief Scientific Officer 1980
Mr. Scott Gleason Sr. VP of Investor Relations 1979
Dr. Clivetty Martinez Chief Compliance Officer NA
Ms. Pamela Wong Chief Legal Officer 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…